Evidence map›Paper›PMID 23442390›Full record

ArticleVirology journal2013

Posttranslational modifications and secretion efficiency of immunogenic hepatitis B virus L protein deletion variants.

Baiba Niedre-Otomere, Ance Bogdanova, Ruta Bruvere, Velta Ose, Wolfram H Gerlich, Paul Pumpens, Dieter Glebe, Tatjana Kozlovska

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Baiba Niedre-OtomereBiomedical Research and Study Centre, Ratsupites street 1, Riga, Latvia. baiba@biomed.lu.lv
Ance Bogdanova
Ruta Bruvere
Velta Ose
Wolfram H Gerlich
Paul Pumpens
Dieter Glebe
Tatjana Kozlovska
Latvian Biomedical Research and Study Centre · LVUniversity of Giessen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSubviral particles of hepatitis B virus (HBV) composed of L protein deletion variants with the 48 N-terminal amino acids of preS joined to the N-terminus of S protein (1-48preS/S) induced broadly neutralizing antibodies after immunization of mice with a Semliki Forest virus vector. A practical limitation for use as vaccine is the suboptimal secretion of such particles. The role of the N-terminal preS myristoylation in the cellular retention of full-length L protein is described controversially in the literature and the relation of these data to the truncated L protein was unknown. Thus, we studied the effect of preS myristoylation signal suppression on 1-48preS/S secretion efficiency, glycosylation and subcellular distribution.

findingsThe findings are that 1-48preS/S is secreted, and that removal of the N-terminal myristoylation signal in its G2A variant reduced secretion slightly, but significantly. The glycosylation pattern of 1-48preS/S was not affected by the removal of the myristoylation signal (G2A mutant) but was different than natural L protein, whereby N4 of the preS and N3 of the S domain were ectopically glycosylated. This suggested cotranslational translocation of 1-48preS in contrast to natural L protein. The 1-48preS/S bearing a myristoylation signal was localized in a compact, perinuclear pattern with strong colocalization of preS and S epitopes, while the non-myristoylated mutants demonstrated a dispersed, granular cytoplasmic distribution with weaker colocalization.

conclusionsThe large deletion in 1-48preS/S in presence of the myristoylation site facilitated formation and secretion of protein particles with neutralizing preS1 epitopes at their surface and could be a useful feature for future hepatitis B vaccines.

Indexed as

Gene DeletionProtein Processing, Post-TranslationalAnimalsAntibodies, NeutralizingAntigens, ViralGenetic VectorsHepatitis B AntibodiesHepatitis B VaccinesHepatitis B virusMiceNeutralization TestsSemliki forest virusViral Envelope ProteinsAntibodies, NeutralizingAntigens, ViralHepatitis B AntibodiesHepatitis B VaccinesL protein, hepatitis B virusViral Envelope Proteins

Identifiers

PMID23442390
PMCPMC3598826
OpenAlexW2118562953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.